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Platinum-based chemotherapy, complemented by surgery,
has dramatically improved the prognosis of metastatic non-
seminomatous germ cell tumours (NSGCT), resulting in cure rates
in excess of 80% (Horwich et al, 1995). The serum markers bhCG
(human chorionic gonadotropin) and aFP (alpha fetoprotein) are
elevated in the majority of these cases at the time of diagnosis. It is
generally accepted that those who do not achieve serological
complete response (CR) after initial chemotherapy require further
treatment in the form of salvage chemotherapy. However, there is
no clear consensus as to the management of patients with serolog-
ical CR. Treatment strategies have included surgery (usually
retroperitoneal lymph node dissection (RPLND)) in all patients
including those with radiological CR (Gelderman et al, 1986;
Fossa et al, 1989; Aass et al, 1991), surgical intervention in those
with residual masses only (Donohue and Rowland, 1984;
Steyerberg et al, 1993) or resection in a selected group of patients
with residual masses (Levitt et al, 1985; Hendry et al, 1993;
Debono et al, 1997). Criteria proposed and used for selection of
these patients have included the size of the mass, the degree of
shrinkage of the mass with chemotherapy, degree of further
shrinkage after chemotherapy and the histology of the primary
tumour (Levitt et al, 1985, Donohue et al, 1987, Fossa et al, 1992,
Hendry et al, 1993, Jaeger et al, 1994, Debono et al, 1997). This is
based on work by authors examining the correlation between
various factors and the histology of the residual mass. These
factors have included the primary histology, marker levels, the
pre- and post-chemotherapy mass size, site of the mass and the
attenuation of the mass on computerized tomographic scanning
(CT) and statistical models have been developed to try to predict
the histology of masses post-chemotherapy (Gelderman et al,
1986; Donohue et al, 1987; Sagalowsky et al, 1990; Stomper
et al, 1991; Steyerberg et al, 1994, 1995; Rabbani et al, 1996). The
rationale behind this is that historically the histology of the
resected material has consisted of necrosis/fibrosis in 18–49%,
differentiated teratoma (TD) in 30–57% and malignancy in up to
30% (Bajorin et al, 1992; Christmas et al, 1998a). While resection
of malignant elements or TD is beneficial, removal of necrotic
or fibrotic tissue is unnecessary. Given the potential morbidity and
mortality of such surgery, not to mention the financial cost, it
would be advantageous to limit this intervention to those cases
where it is warranted.
The best approach for radiological residual masses is not clear
in patients who have achieved a serological CR. Some advocate
observation if initial chemotherapy leads to >90% radiological
regression (Gelderman et al, 1986). The policy at Mount Vernon
Hospital has been that patients with serological and radiological
CR have not been submitted to routine RPLND. The policy in
patients with serological CR but residual radiological abnormali-
ties in whom there is a high likelihood of residual TD was to
perform resection, while those in whom this risk was considered
low were placed on close observation with serial repeat scanning.
Factors favouring observation were > 50% tumour volume reduc-
tion, absence of cystic change on CT, absence of TD in the primary
tumour, and size of residual mass ≤ 2 cm. In this retrospective
Long-term follow-up of residual masses after
chemotherapy in patients with non-seminomatous germ
cell tumours
MP Napier1, A Naraghi1, TJ Christmas2 and GJS Rustin1
1Department of Medical Oncology, Centre for Cancer Treatment, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN; 2Department
of Urology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
Summary This retrospective study was undertaken to determine the outcome of patients with non-seminomatous germ cell tumour who
achieved a serological complete response but who had residual radiologic abnormalities upon completion of primary platinum-based
chemotherapy. This was an analysis of 76 consecutive patients treated at Mount Vernon Hospital between 1983 and 1997. The patients were
placed into two groups based upon whether they had surgical resection (surgery group, 48 patients) or observation (observation group, 28
patients) of residual radiologic masses on completion of initial chemotherapy (to enter the surgery group, complete surgical resection must
have been achieved). The primary end-points were progression-free and overall survival. The percentage of patients alive with median follow-
up 66 months was 90% for the surgery group and 80% for the observation group (P = 0.53, not significant). The percentage of patients
continuously disease-free was 70% in the surgery group and 80% in the observation group (P = 0.31, not significant). In the small sub-group
of patients with differentiated teratoma (TD) in the primary lesion who were observed, there was no excess risk of relapse or death. Patients
who achieve a serological complete response after primary chemotherapy, but are left with ≤ 2 cm radiological masses that are not cystic and
have responded, can be safely observed with diligent follow-up. © 2000 Cancer Research Campaign
Keywords: testicular neoplasms; surgery; retroperitoneal lymph node dissection
1274
Received 10 January 2000
Revised 18 May 2000
Accepted 27 June 2000
Correspondence to: GJS Rustin
British Journal of Cancer (2000) 83(10), 1274–1280
© 2000 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1416, available online at http://www.idealibrary.com on analysis we report our experience with 76 patients with an incom-
plete radiological response in the presence of normal serum
tumour markers and examine the outcome in those not submitted
to surgery compared to those where surgery was undertaken.
PATIENTS AND METHODS
A retrospective analysis of the medical records of 76 patients with
primary testicular or primary retroperitoneal NSGCT was
performed. These patients had their cancer diagnosed between
January 1980 and January 1998. The patients were identified from
a database of all patients with testicular cancer referred to Mount
Vernon Hospital during these times. This database was correlated
with the database from the local Cancer Registrary Office (Mount
Vernon site) of all patients in the district with a diagnosis of 
testicular cancer.
Patients were considered eligible for analysis if they had Royal
Marsden Stage II, III or IV primary testicular or primary retroperi-
toneal NSGCT, and achieved a complete serological response (i.e.
normalization of aFP and bhCG if elevated pre-chemotherapy)
but who had potentially resectable residual disease on post-
treatment CT scanning. On entry the following data was collected:
1. Serial pre-, on-treatment and post-chemotherapy tumour
markers analysis (aFP and bhCG)
2. Results from pre-, on-treatment and post-chemotherapy CT
and other radiographic examinations
3. Pathology results from diagnostic orchidectomy or biopsy, and
4. Pathology results of the resected mass in those who underwent
post-chemotherapy surgery. Pathology was classified
according to the terminology of the British Testicular Tumour
Panel (Pugh, 1976).
No patients were excluded because of missing data.
Patients were excluded if they had Royal Marsden Stage I or IM
disease, pure seminoma or primary mediastinal disease. Patients
were also excluded if residual disease was deemed inoperable 
(e.g. bony metastases) or if serological or radiological progression
occurred prior to planned post-treatment surgery.
All patients received platinum-based chemotherapy which was
considered standard for that time or were entered in the Medical
Research Council (UK) Testicular Cancer chemotherapy trials.
Decisions regarding post-treatment surgery or surveillance were
based upon CT scanning within 4 weeks of the final cycle of
chemotherapy. Residual disease in the observation group was
considered to be radiological abnormality in the region of previous
measurable tumours which persisted for at least two post-
treatment scans at least 8 weeks apart. If immediate surgery was
proposed then this was usually performed within 8 weeks of the
final cycle of chemotherapy.
Study design
This study was a retrospective analysis of progression-free (PFS)
and overall (OS) survival of patients meeting the inclusion criteria.
The aim of the study was to determine the outcome of those
patients in this group who underwent post-treatment surgery and
of those who were subjected to a policy of ‘expectant’ surveil-
lance. Patients who had a policy of surveillance tended to have had
a TD-negative primary and had post-chemotherapy residual
disease of ≤ 2 cm maximum diameter which were not cystic on CT
scanning. There were variations from these guidelines according
to patient and physician preference.
On meeting the inclusion criteria the patients were divided into
two groups:
Group 1 – Surgery: patients who achieved a serological complete
response (or whose markers remained normal) and who were
left with potentially resectable radiological abnormalities who
underwent immediate (within 8 weeks) surgery. Surgery
usually consisted of RPLND, metastatectomy, or both.
Group 2 – Observation: patients who achieved a serological
complete response (or whose markers remained normal) and
who were left with potentially resectable radiological abnor-
malities who had a policy of active surveillance without
surgery.
Study end-points for each patient were date of death or date of
progression. For those who had not died or progressed the censure
date was date of last contact (either clinic visit or tumour marker
assessment).
Statistical analysis
Kaplan–Meier (Kaplan and Meier, 1958) survival and progression-
free survival curves were calculated for each group. Overall
survival was defined from the date of histological diagnosis 
of cancer to date of death or last follow-up evaluation. Progression-
free survival was defined from the date of histological diagnosis of
cancer to date of serological or radiological progression (whichever
was earlier) or last follow-up evaluation. Comparisons were evalu-
ated for significance using the Cox–Mantel log-rank test (Peto et
al, 1977).
RESULTS
342 patients with testicular cancer were diagnosed in the area
served by the regional Cancer Registary Office or who referred to
Mount Vernon Hospital during the period January 1983 to January
1998. 183 had undergone platinum-based chemotherapy. From 
a review of this database 77 patients fitted the eligibility criteria.
One of these patients was excluded as the hospital notes had been
destroyed. The 76 remaining patients were divided into two groups
based upon post-chemotherapy surgery or observation. The patient
characteristics are given in Table 1.
Group 1 – Surgery
Forty-eight patients achieved serological CR but had residual
resectable disease and subsequently underwent surgery. Individual
patient characteristics and the histological assessment of the
residual disease is shown in Table 2. In the resection specimen
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Table 1 Patient demographics
Group 1 – Surgery Group 2 – Observation
Patients (n)4 8 2 8
Median age at diagnosis (years) 28 27
Range 16–49 18–39
Median follow-up (months) 66 79
Range 13–153 20–17250% of patients had TD or a combination of TD and necrotic
tissue/fibrosis, 31.25% had necrotic tissue/fibrosis only and
18.75% had residual active tumour.
Four of these 48 patients have subsequently relapsed and died
from progressive NSGCT. Of these, three had active tumour in the
resection specimen and the other had necrosis only. Four others
relapsed radiologically but were found to have TD at subsequent
resection. Two others relapsed with active NSGCT but have been
rendered disease-free with salvage chemotherapy and surgery
(RPLND). One further patient relapsed with a second primary
testicular cancer (seminoma).
Group 2 – Observation
Twenty-eight patients achieved a serological complete response
but had residual radiological abnormalities which were deemed
potentially operable. The patient characteristics of this group are
shown in Table 3. Three patients (numbers 5, 19 and 28) had
residual radiological masses < 1 cm in diameter (considered
within the normal range for lymph nodes on CT) but were
included in this analysis as these abnormalities were thought to be
in the same area as previous tumour deposits and have persisted
for the entire follow-up period.
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Table 2 Surgical group
Patient number Age at diagnosis Stage at diagnosis IGCCCG Histology Size of residual Histology of
prognostic group of primary after chemotherapy resection specimen
1 34 IIIc Good MTI 5 cm TD
2 31 IIa Good MTU 1 cm Necrosis
3 26 IVL3 Good MTU 13 cm Necrosis
42 9 1 ° retroperitoneal Good MTU 5 cm TD
5 28 IIb Intermediate MTI 2 cm Necrosis
6 33 IIc Poor MTU 9 cm Carcinoma
7 21 IIc Good MTU 2 cm Necrosis
8 21 IIc Good MTU 2.5 cm TD
9 24 IIc Good MTI 8 cm MTI
10 35 IIa Good MTI 3.5 cm TD
11 33 IIIc Intermediate MTI 18 cm TD
12 30 IIIc Poor MTU 7 cm Necrosis
13 38 IIIc Good MTI 4 cm Necrosis
14 27 IIIc Intermediate MTI 7 cm Necrosis
15 16 IIc Good MTI 3 cm TD
16 29 IIa Good MTI 2 cm TD
17 31 IIa Good MTI 2 cm TD
18 22 IIIc Good MTI 7 cm MTI
19 26 IIa Good MTI 1.5 cm TD
20 24 I relapse IIa Good MTI 11.2 cm TD
21 36 IIb Good MTU 1.3 cm Necrosis
22 21 IIc Good MTI 10 cm TD
23 23 IVL3 Poor MTT 4 cm Necrosis + choriocarcinoma
(as hCG immunostaining positive)
24 28 IIb Good MTI 5 cm TD
25 35 IIb Good MTI 1.8 cm TD
26 31 IIb Good MTI 3 cm TD
27 19 IV Poor MTI 8 cm TD
28 23 IVL3 Poor MTU 4 cm TD
29 26 IVL2 Good MTU 13 cm TD
30 32 IVL3 Intermediate MTT 3 cm Necrosis
31 34 IV Poor MTU 6 cm Necrosis
32 49 IVL1 Good MTI 1.8 cm MTI (+ immature adipose tissue)
33 21 IVL3 Good MTU 2 cm TD + sarcoma
34 28 IVL3 Poor MTU 3 cm TD
35 20 IVL3 Intermediate MTU 1.5 cm Necrosis
36 18 IVL3 Intermediate MTI 8 cm TD
37 44 IIc Good MTI 5 cm TD
38 19 IVL3 Poor MTI 1.5 cm TD
39 22 IV H+ Poor MTU 10 cm Necrosis
40 29 IVL3 Good MTI 3 cm Necrosis
41 37 IVL3 Poor MTI 5 cm Necrosis + yolk sac tumour
42 38 IIc Good MTU 1.5 cm TD + myxoid yolk sac tumour
43 27 IIc Intermediate MTI 2.5 cm TD
44 23 IVL2 Good MTU 1.3 cm Necrosis
45 21 IIb Good MTU 0.8 cm Necrosis
46 39 IIc Intermediate MTU 13 cm TD
47 37 IVL3 Intermediate MTU 10 cm TD
48 37 I relapse IIa Good MTU 2 cm TD
IGCCCG = International Germ Cell Cancer Collaborative Group; MTI = malignant teratoma, intermediate; MTT = malignant teratoma, trophoblastic;
MTU = malignant teratoma, undifferentiated; hCG = human chorionic gonadatrophin; TD = differentiated teratoma. Size was determined as the maximum
tumour diameter in any plane. Histology is according to the classification of Pugh (1976)Of these 28 patients, two have subsequently died, one from
relapsed NSGCT and one from a motor-vehicle accident. A total
of six patients have relapsed, of whom five had relapse chemo-
therapy and four of these went on to have surgery. One patient
(number 13) had surgery alone. The histology of the resected
tissue in those patients who went to surgery is shown in Table 3.
Relapses have occurred in two of eight patients with TD in
the primary tumour and in four of 20 patients without TD in the
primary tumour.
Two of these patients who relapsed but are now disease-free are
interesting. Both had TD in the primary testicular cancer. One had
residual disease around the (L) brachial plexus which at initial
thoracotomy was deemed unresectable, but after later marker
relapse and salvage chemotherapy, successful resection of residual
active disease was performed at a surgical unit specializing in
brachial plexus injuries. The other patient had initial RMH Stage
IV malignant teratoma trophoblastic (MTT) and had resection of
residual necrotic tissue and TD from para-aortic lymph nodes. A
small peripheral lung lesion was seen at the initial post-treatment
staging CT scan but the patient was observed because of his fragile
psychological state at that time. This patient subsequently had a
marker relapse some 18 months later. CT and positron-emission
tomographic (PET) scanning suggested that the lung lesion was
the sole site of disease. Resection of this nodule showed active
choriocarcinoma. He has been observed without further chemo-
therapy and is now disease-free some 20 months later.
Six further patients who had TD in the primary testicular cancer
had residual radiological changes and avoided surgery. Two of
these had radiological changes which resolved over periods of 6
and 12 months (patients number 16 and 17). Four patients continue
to have minor radiographic changes (patients number 1, 4, 7 and
26). One patient (number 26) refused surgery.
Comparisons between the two groups in terms of initial stage,
prognostic group and histology is given in Table 4. Patients with
TD in the primary tumour were more likely to have had surgery
rather than observation.
Residual masses after non-seminomatous germ cell tumours 1277
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Table 3 Observation group. Three patients had residual disease > 3 cm. Patient 26 refused surgery. The residual disease in patients 6 and 27 showed
incomplete resolution on subsequent CT scanning
Patient number Age at diagnosis Stage at diagnosis IGCCCG Histology Size of residual Histology of
prognostic group of primary after chemotherapy resection specimen
if relapsed
1 31 IIb Good MTI 1 cm
2 39 IVL2 Good MTU 2 cm
3 35 IVL3 Intermediate MTU 1 cm
4 27 IIb Intermediate MTI 1 cm
5 32 IIa Good MTU 0.3 cm
6 23 IIb Good MTU 2.5 cm
7 19 IVL3 Poor MTI 1.5 cm
8 38 IIc Good MTU 1.5 cm
9 27 IIc Good MTU 1.5 cm TD
10 23 IIc Poor MTU 1.8 cm
11 34 IV Poor MTU 2 cm
12 32 IVL3 Poor MTT 1 cm
13 18 IVL3 Intermediate MTI 2 cm Choriocarcinoma
14 27 IIb Good MTU 1.5 cm
15 34 IIc Intermediate MTI 2 cm TD
16 23 IIc Good MTI 2 cm
17 21 IVL3 Intermediate MTU 1 cm
18 27 IVL3 Good MTU 1 cm
19 33 IVL3 Intermediate MTU 0.8 cm
20 35 IVH+ Poor MTU 1 cm
21 36 III Good MTT 1 cm MTI
22 26 IIb Good MTU 2 cm MTU
23 24 IVL1 Good MTI 2 cm
24 27 IIIb Good MTU 2 cm
25 37 IVL3 Intermediate MTU 2 cm
26 21 IVL1 Intermediate MTI 3 cm
27 31 IVL3 Good MTU 3 cm
28 27 IIb Good MTU 0.6 cm
IGCCCG = International Germ Cell Cancer Collaborative Group; MTI = malignant teratoma, intermediate; MTT = malignant teratoma, trophoblastic; 
MTU = malignant teratoma, undifferentiated; TD = differentiated teratoma. Histology is according to the classification of Pugh (1976)
Table 4 Patient characteristics according to initial stage, histology and size
of residual tumour
Surgery Observation
% RMH stage
Stage II 52 43
Stage III 10.5 7
Stage IV 37.5 50
% IGCCCG prognostic group
Good 60.5 53.5
Intermediate 18.5 28.5
Poor 21 18
% Histology of primary
MTT 4 7
MTU 44 64
MTI 52 29
Average size residual mass 5.4 cm 1.6 cm
(largest)Overall survival and progression-free survival
Kaplan–Meier estimates of overall survival were calculated for
each group and the survival curves are shown in Figure 1. There
was no significant difference in survival between the two groups
(P = 0.53; Cox–Mantel log-rank). Similar progression-free
survival curves are shown in Figure 2. Again there was no signifi-
cant difference between the two groups (P = 0.31; Cox–Mantel
log-rank).
An attempt to correlate individual cause-specific deaths was
made with initial International Germ Cell Cancer Collaborative
Group (IGCCCG, 1997) prognostic group (patients were allocated
a prognostic group retrospectively). The results are shown in Table 5.
Because of the small number of deaths in each group there was no
significance in the result.
Overall survival in surgical group with respect to
resection histology
Figure 3 shows the overall survival in the surgical group according
to histology of the resected specimen. As expected, the finding of
active NSGCT was associated with a significantly worse prog-
nosis (P = 0.02; Cox–Mantel log-rank) than in those patients who
had differentiated teratoma or necrosis/fibrosis only.
DISCUSSION
Since the advent of platinum-based chemotherapy, the outlook for
patients with NSGCT has been extremely favourable. Post-
chemotherapy surgery is often helpful in achieving cure. It is also
useful in eradicating residual TD and in guiding clinicians as to
whether further chemotherapy is appropriate. The most common
surgical approach, RPLND, is not without risk, however, and long-
term morbidity is common even in experienced hands. The
histology of resected residual tissue in the surgery group presented
here (differentiated teratoma 50%, necrosis/fibrosis 31.75%,
active cancer 18.75%) is similar in content to two recently
published large combined series (Steyerberg et al, 1997; Stenning
et al, 1998). Overall and progression-free survival curves were
also similar.
Whether this surgical approach should be offered to all patients
regardless is currently a matter of some debate. The utility of the
germ cell tumour markers aFP and bhCG must also be taken in-
to consideration. Most clinicians would not now routinely offer
RPLND in patients with both radiological and serological
complete responses. There are, however, a group of patients who
have serologic complete responses but with residual radiographic
abnormalities and these patients always give cause for concern.
Of these, the patients with TD in the primary tumour are an
important sub-group, as incomplete resection of TD may lead to
late relapse in the form of de-differentiated tumour (Christmas
et al, 1998b).
Despite the importance of this group of patients there have been
relatively few publications dealing with this issue. The Indiana
group (Debono et al, 1997) have recently reported their experience
with disseminated NSGCT. Among the groups of patients reported
they described 10 patients with TD-positive primary tumours with
residual radiologic abnormalities in the face of normal serum
tumour markers. In nine of these patients the radiological 
abnormalities subsequently resolved and in only one has there
been relapse (in a separate site). A separate group of 27 patients
with TD-negative primary tumours with residual radiological
abnormalities was also described. Of these patients three
progressed at the site of residual radiological abnormality within
10 months and one relapsed after 4 years with disseminated
disease. The radiological abnormalities in the other 23 all resolved
but two have relapsed subsequently (both at the sites of previous
disease).
Jones et al (1998), described 101 patients with normal serum
tumour markers at the end of chemotherapy with at least one
residual mass under close observation and no malignant teratoma
resected from other sites. In this group 35 have subsequently
progressed, and of these 23 have died from progressive NSGCT
and three have died from other causes. In the group without subse-
quent progression five have died from non-cancer causes. There
was little difference in the chance of progression whether the
remaining radiological abnormality was in the lung or abdomen.
There was also no clear predictive value of either pre- or post-
chemotherapy mass size on the chances of relapse. The risk of
relapse was, however, higher in patients with more than one site of
1278 MP Napier et al
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Figure 1 Overall survival
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Figure 2 Progression-free survival
Table 5 Deaths according to initial prognostic group
Deaths in surgical group Deaths in observation
group
IGCCCG prognostic group
Good 2/29 0/15
Intermediate 1/9 0/8
Poor 2/10 1/5residual radiological abnormality. Radiotherapy was not routinely
given to residual masses in this study except at one centre. At this
centre there was no involved site progression noted in any of 19
patients treated, however in none of these reported patients was
there complete regression seen with radiotherapy.
In our series of 28 patients with residual radiological abnormal-
ities, six have subsequently relapsed and one patient has died of
NSGCT. The patient who died relapsed in multiple sites. The other
relapses were in sites of known residual masses (four in retroperi-
toneal lymph nodes and one in lung). Four of these patients have
been effectively salvaged with a combination of surgery (RPLND)
and chemotherapy (two had TD and two had active NSGCT in the
resected specimen), and one other has been effectively salvaged
with surgery alone (choriocarcinoma in the resected specimen).
The overall survival in this group is excellent. 22 of 28 patients
(79%) thus avoided potentially morbid surgery.
Of some interest in this group is the low rate of radiographic
resolution of residual tumour mass in patients who had TD in the
primary cancer. Of these eight patients only two had radiographic
resolution, albeit incomplete (both had residual disease > 2 cm;
patients number 6 and 27 in Table 3), and two had disease progres-
sion. This is compared with the Indiana experience in which nine
of 10 residual masses resolved (Debono et al, 1997). Our results
are more in line with the results from the UK Medical Research
Council’s TE16 trial (Jones et al, 1998), where the spontaneous
regression rates were 33% in lung and 39% in retroperitoneal
nodes.
Our results suggest that residual radiographic abnormalities
(size  ≤ 2 cm) in patients with complete serologic responses can be
safely observed without detriment in terms of progression-free and
overall survival. Of course, the two groups are not evenly matched
in terms of residual mass size (only three patients in the observa-
tion group had residual radiologic abnormalities > 2 cm and one of
these refused surgery) or the presence or absence of TD in the
primary (interestingly they were well matched in terms of initial
Royal Marsden stage and IGCCCG prognostic group, Table 3).
Correctly selecting patients who would benefit from surgery
would obviously remove from the observation group those at
greatest risk of relapse. Steyerberg et al (1998) recently examined
the principles of observation and resection in patients with residual
masses < 2 cm. They concluded that with currently available
‘evidence’ (i.e. data from resection histology of small masses: 4%
had cancer if the residual mass was 0–1 cm, and 7% had cancer if
the residual mass was 1–2 cm in size) a randomized clinical trial to
‘answer’ this important question would never be feasible. For a
survival advantage of just 3% at 5 years, at a conservative estimate
2800 patients would need to be randomized. For an observational
study it is possible that even greater numbers of patients will be
needed to overcome an uneven distribution in patients. The same
authors, using a decision analysis model, tested this assumption
and estimated a 5-year survival advantage of 2.7–4.3% for resec-
tion of masses < 2 cm in all cases (Steyerberg et al, 1999).
Laparoscopic retroperitoneal lymphadenectomy might prove to
be a useful and less morbid alternative to open surgery in selected
patients. Janetschek et al (1999) have recently published their
results in 24 patients submitted to this procedure. The perioperative
complication rate was low and anterograde ejaculation was
preserved in all cases. Of interest is that of the eight residual masses
< 1 cm which were resected, seven contained necrotic tissue only.
At present it remains reasonable that all patients with residual
masses at the completion of chemotherapy should be considered
for surgery, but there is a smaller subset in whom close observation
could be considered. If these patients are deemed suitable candi-
dates for observation then they could be spared the morbidity of
surgery. The usefulness of new scanning modalities such as PET to
distinguish between active tumour and necrosis has yet to be
confirmed. Laparoscopic retroperitoneal lymphadenectomy might
also prove to be a useful less-morbid procedure in selected
patients. Whether these techniques can be used to safely defer
radical surgery is a question for the future.
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